Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.

ABSTRACT:

Background

Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited.

Methods

This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included. Treatment-related adverse events (trAEs) were graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) were evaluated by Response Evaluation Criteria in Solid Tumors V.1.1 when available. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method.

Results

Among 110 pts, median age at ICI initiation was 65 (IQR: 59-75). Median follow-up time

SUBMITTER: Nassar AH 

PROVIDER: S-EPMC11877189 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature